 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
67 News |  |
| 12» |
- Breyanzi (lisocabtagene maraleucel) / BMS, avipendekin pegol (NKTR-255) / Nektar Therap
ENHANCED CAR T-CELL EXPANSION AND DURABLE COMPLETE RESPONSES WITH NKTR-255 PLUS LISOCABTAGENE MARALEUCEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (Brown Hall 1) - May 15, 2025 - Abstract #EHA2025EHA_3461;
P1
Higher CAR T-cell expansion and AUC0-28 were observed in pts treated with the OBR compared to liso-cel alone. CRs appear to be durable, with only one relapse.
- || Bavencio (avelumab) / EMD Serono
Trial completion date, Trial primary completion date: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) (clinicaltrials.gov) - May 6, 2025
P2, N=256, Active, not recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
CRs appear to be durable, with only one relapse. Trial completion date: Jan 2025 --> Jul 2026 | Trial primary completion date: Jan 2025 --> Jun 2025
- Breyanzi (lisocabtagene maraleucel) / BMS, avipendekin pegol (NKTR-255) / Nektar Therap
Enhanced CAR T (Cinema Corso) - May 4, 2025 - Abstract #ICML2025ICML_1083;
- avipendekin pegol (NKTR-255) / Nektar Therap
Chemokine engineering significantly enhanced migration and tumor infiltration of ex vivo-expanded natural killer cells in osteosarcoma (Section 37; Poster Board No: 3) - Mar 25, 2025 - Abstract #AACR2025AACR_3201;
To evaluate NK cell tumor infiltration, we injected human NK cells with an IL-15 agonist, NKTR-255, and harvested and dissociated tumors 5-7 days after NK injection for flow cytometry analysis...Our in vitro and in vivo data demonstrated that secretion of CXCL9, -10, and -11 from OS significantly enhanced NK migration and NK infiltration into the OS TME. We are actively investigating the in vivo anti-tumor efficacy of expanded NK cells against CXCL9, -10, or -11-secreting disseminated OS tumors.
- | avipendekin pegol (NKTR-255) / Nektar Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma (clinicaltrials.gov) - Feb 13, 2025
P2/3, N=15, Terminated, Sponsor: Nektar Therapeutics
We are actively investigating the in vivo anti-tumor efficacy of expanded NK cells against CXCL9, -10, or -11-secreting disseminated OS tumors. N=400 --> 15 | Trial completion date: Jan 2029 --> Aug 2024 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> May 2024; Sponsor decided to end the study
- Anti-MCAM CAR NK / New York Medical College, avipendekin pegol (NKTR-255) / Nektar Therap
Combinatorial Immunotherapy of Mcam Targeting Chimeric Antigen Receptor Modified Expanded Natural Killer Cells and IL-15 Agonist Against Neuroblastoma (HCC Ballroom C; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1366;
Combination with NKTR-255 further enhanced the anti-tumor effects of CAR NK cells (p < 0.001 compared to vehicle control, p < 0.05 compared to CAR NK), and further prolonged animal survival (100% vs 30% survival at day 126 compared to CAR NK, p < 0.05) (Fig 1D, E). Conclusions Our studies demonstrate that ex vivo expanded and modified anti-MCAM CAR NK cells alone and/or in combination with NKTR-255 are promising novel alternative therapeutic approaches to targeting MCAM high malignant NB.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma, avipendekin pegol (NKTR-255) / Nektar Therap
Targeting Ewing Sarcoma By IL1RAP CAR Modified Ex-Vivo Expanded TGF? Imprinted NK Cells in Combination with IL-15 Agonist and Anti-GD2 Antibody (HCC 313 ABC; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_728;
Conclusions Our data demonstrated enhanced anti-tumor efficacy of IL1RAP CAR NK/TGF?i-NK cells alone and combined with NKTR-255 and dinutuximab against ES in vitro and in vivo. These CAR engineered TGF?i NK cells in combination with NK function and persistence enhancing immune modulators constitute potential novel effective immunotherapies for patients with high-risk ES.
- avipendekin pegol (NKTR-255) / Nektar Therap
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL) (HCC Ballroom B; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_713;
P1, P2/3
All patients received CD19-CAR-T cell therapy and ?1 dose of study treatment; 12/15 (80%) received axi-cel and 3/15 (20%) received liso-cel. In total, 11 were randomized to the NKTR-255 (5 at 1.5
- avipendekin pegol (NKTR-255) / Nektar Therap
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL) (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3791;
P1, P2/3
Conclusions : Preliminary data from the randomized, double-blind, placebo-controlled study showed NKTR-255 adjuvant to CD19 CAR-T cell therapy in LBCL was well-tolerated, safe and efficacious to enhance the CR rate of CD19 CAR-T cell therapy alone at month 6. Additional confirmatory studies with NKTR-255 as adjuvant treatment to CAR-T therapy and other cellular therapies are warranted.
- NKTR-255 / Nektar Therap
REStoring lymphoCytes using NKTR-255 after chemoradiothErapy in solid tumors (RESCUE): preplanned interim safety and efficacy analysis (Exhibit Halls AB - George R. Brown Convention Center) - Oct 30, 2024 - Abstract #SITC2024SITC_1938;
P2
Additional confirmatory studies with NKTR-255 as adjuvant treatment to CAR-T therapy and other cellular therapies are warranted. Methods NKTR-255 (3
- || NKTR-255 / Nektar Therap
P1 data, Journal, CAR T-Cell Therapy: A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. (Pubmed Central) - Oct 17, 2024
P1
The increase in chemokines was associated with decreases in absolute lymphocyte counts and CD8+ CAR T-cells in blood and ten-fold increases in CSF CAR-T cells, suggesting lymphocyte trafficking to tissue. Combining NKTR-255 with CAR19-22 was safe, feasible and associated with high rates of durable responses (NCT03233854).
- ||| Bavencio (avelumab) / EMD Serono
Enrollment closed: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) (clinicaltrials.gov) - Jul 25, 2024
P2, N=256, Active, not recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Combining NKTR-255 with CAR19-22 was safe, feasible and associated with high rates of durable responses (NCT03233854). Recruiting --> Active, not recruiting
- NKTR-255 / Nektar Therap
Phase classification, Combination therapy, Monotherapy: Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov) - May 13, 2024
P1/2, N=25, Completed, Sponsor: Nektar Therapeutics
Recruiting --> Active, not recruiting Phase classification: P1b/2 --> P1/2
- || C-TIL051 / AbelZeta Pharma
Enrollment open, Metastases: C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 1, 2024
P1, N=20, Recruiting, Sponsor: AbelZeta, Inc.
Phase classification: P1b/2 --> P1/2 Not yet recruiting --> Recruiting
- | avipendekin pegol (NKTR-255) / Nektar Therap
Enrollment closed: IRB-41382: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies (clinicaltrials.gov) - Feb 28, 2024
P1, N=56, Active, not recruiting, Sponsor: Crystal Mackall, MD
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | avipendekin pegol (NKTR-255) / Nektar Therap
Trial completion date, Trial primary completion date, Combination therapy, CAR T-Cell Therapy: NCI-2022-02316: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - Feb 15, 2024
P1, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Dec 2024
- | C-TIL051 / AbelZeta Pharma
Trial completion date, Trial primary completion date, Metastases: C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 31, 2023
P1, N=20, Not yet recruiting, Sponsor: AbelZeta, Inc.
- Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma, NKTR-255 / Nektar Therap
Targeting Ewing Sarcoma By Genetically and Epigenetically Modified Ex-Vivo Expanded NK Cells in Combination with NKTR-255 and Dinutuximab (221 (Meeting Level, Henry B. Gonzalez Convention Center); in-person) - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_739;
Conclusions Our data demonstrated enhanced anti-tumor efficacy of modified NK (IL1RAP CAR NK, TGF?i-NK, IL1RAP CAR CXCR2 NK) cells alone and combined with NKTR-255 and dinutuximab against ES in vitro. This provided a rationale for a preclinical evaluation of the anti-tumor effects of these modified NK cells combined with NKTR-255 and dinutuximab in vivo.
- || P2 data, Journal: Multizentrische, randomisierte, offene Parallelarm-Umbrella-Studie JAVELIN Bladder Medley der Phase II zu Avelumab (MSB0010718C) in Kombination mit Sacituzumab Govitecan, M6223 und NKTR-255 als Erhaltungstherapie bei Teilnehmern mit lokal fortgeschrittenem oder metastasiertem Urothelkarzinom, deren Erkrankung unter einer platinhaltigen Erstlinien(1L)-Chemotherapie nicht fortgeschritten ist. (Pubmed Central) - Nov 21, 2023
This provided a rationale for a preclinical evaluation of the anti-tumor effects of these modified NK cells combined with NKTR-255 and dinutuximab in vivo. No abstract available
- Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, NKTR-255 / Nektar Therap
Optimizing Ex-Vivo Expanded NK Cell- Mediated Cellular Cytotoxicity By Obinutuzumab Combined with NKTR-255 in Burkitt Lymphoma (BL) (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2497;
The in vivo effects of NKTR-255 with expanded NK cells and Obinutuzumab against rituximab-resistant BL cells using humanized NSG models are very promising. Mechanisms studies of BL relapsed from the combination therapy are under investigation.
- || C-TIL051 / AbelZeta Pharma
Trial initiation date, Metastases: C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 15, 2023
P1, N=20, Not yet recruiting, Sponsor: Cellular Biomedicine Group, Inc.
Mechanisms studies of BL relapsed from the combination therapy are under investigation. Initiation date: Mar 2023 --> Dec 2023
- || Bavencio (avelumab) / EMD Serono
Trial completion date, Trial primary completion date: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) (clinicaltrials.gov) - Aug 1, 2023
P2, N=252, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Initiation date: Mar 2023 --> Dec 2023 Trial completion date: Aug 2026 --> Jan 2025 | Trial primary completion date: Aug 2026 --> Jan 2025
- NKTR-255 / Nektar Therap
Restoring Lymphocytes Using NKTR-255 after Chemoradiotherapy in Solid Tumors (RESCUE) (Exhibit Hall) - Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2192;
P2
We plan to accrue 30 patients with locally advanced NSCLC who received standard CRT followed by one year of durvalumab. N/A
- || NKTR-255 / Nektar Therap
Trial completion: NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 15, 2023
P1, N=30, Completed, Sponsor: Nektar Therapeutics
N/A Active, not recruiting --> Completed
- || avipendekin pegol (NKTR-255) / Nektar Therap
Enrollment open, Trial initiation date: REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) (clinicaltrials.gov) - Jun 8, 2023
P2, N=39, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jan 2023
- ||| NKTR-255 / Nektar Therap
Trial completion, Enrollment change, Trial completion date, Combination therapy, Monotherapy: Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov) - May 16, 2023
P1b/2, N=25, Completed, Sponsor: Nektar Therapeutics
Not yet recruiting --> Recruiting | Initiation date: Apr 2023 --> Jan 2023 Active, not recruiting --> Completed | N=326 --> 25 | Trial completion date: Aug 2024 --> Mar 2023
- || NKTR-255 / Nektar Therap
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 12, 2023
P1, N=30, Active, not recruiting, Sponsor: Nektar Therapeutics
Active, not recruiting --> Completed | N=326 --> 25 | Trial completion date: Aug 2024 --> Mar 2023 Enrolling by invitation --> Active, not recruiting | N=118 --> 30 | Trial completion date: Oct 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023
- ||| NKTR-255 / Nektar Therap
Enrollment closed, Combination therapy, Monotherapy: Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov) - Mar 17, 2023
P1b/2, N=326, Active, not recruiting, Sponsor: Nektar Therapeutics
Enrolling by invitation --> Active, not recruiting | N=118 --> 30 | Trial completion date: Oct 2023 --> Jun 2023 | Trial primary completion date: Mar 2023 --> Jun 2023 Recruiting --> Active, not recruiting
- Danyelza (naxitamab) - Y / mAbs Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma, NKTR-255 / Nektar Therap
Novel humanized anti-GD2 antibody inhibits GD2-mediated immunosuppression by targeting GD2+ breast cancer stem-like cells (Section 22; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_7452;
Combination of naxitamab with macrophages induced macrophage mediated phagocytosis TNBC cells. NK cells were more stable and cytotoxic when generated with NKTR-255 vs.
- Venclexta (venetoclax) / Roche, AbbVie, NKTR-255 / Nektar Therap
B7-H3 blockade in combination with natural killer cell activity enhancers including NKTR-255 and venetoclax synergistically induces cytotoxicity in B7-H3+ AML cells (Section 22; Poster Board #1) - Mar 14, 2023 - Abstract #AACR2023AACR_7436;
NK cells were more stable and cytotoxic when generated with NKTR-255 vs. Our data demonstrate that blockade of the immune checkpoint protein, B7-H3 with the IL-15 receptor agonist, NKTR-255, or the BCL2 inhibitor, ABT-199, synergistically induces NK cell mediated cytotoxicity against B7-H3+ AML cells.
- NKTR-255 / Nektar Therap
NKTR-255, a polymer-conjugated IL-15, dramatically improves ROR1 CAR-T cell persistence and anti-tumor efficacy in an autochthonous model of ROR1+ lung cancer (Valencia BC - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_3172;
Together, our work shows that NKTR-255 dramatically improves the persistence, function, and anti-tumor activity of ROR1 CAR-T cells in an aggressive autochthonous model of ROR1+ lung cancer. Our findings provide rationale to combine NKTR-255 with CAR-T cell therapy as a strategy to enhance the anti-tumor efficacy of CAR-T cells in patients with solid tumors.
- || C-TIL051 / AbelZeta Pharma
New P1 trial, Metastases: C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 9, 2023
P1, N=20, Not yet recruiting, Sponsor: Cellular Biomedicine Group, Inc.
- |||||| avipendekin pegol (NKTR-255) / Nektar Therap
Enrollment open: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma (clinicaltrials.gov) - Jan 4, 2023
P2/3, N=400, Recruiting, Sponsor: Nektar Therapeutics
Our findings provide rationale to combine NKTR-255 with CAR-T cell therapy as a strategy to enhance the anti-tumor efficacy of CAR-T cells in patients with solid tumors. Not yet recruiting --> Recruiting
- |||||||||| avipendekin pegol (NKTR-255) / Nektar Therap
New P2/3 trial: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma (clinicaltrials.gov) - Dec 23, 2022
P2/3, N=400, Not yet recruiting, Sponsor: Nektar Therapeutics
- NKTR-255 / Nektar Therap
Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_903;
P1
NKTR-255 administered at 1.5mcg/kg following CAR-T cell therapy was safe and appeared to promote CAR expansion in CNS and peripheral blood. Dose escalation is ongoing; additional safety data and longitudinal correlative assessments, including qPCR and cytokine data, will be presented at the meeting.
- || avipendekin pegol (NKTR-255) / Nektar Therap
New P2 trial: REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) (clinicaltrials.gov) - Dec 1, 2022
P2, N=39, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- NKTR-255 / Nektar Therap
A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) () - Nov 29, 2022 - Abstract #ASH2022ASH_7804;
P1
Conclusion s : This clinical trial will evaluate the safety and efficacy of NKTR-255 in combination with liso-cel aiming to increase the response rates and durability of response compared with CD19 CAR-T cells alone. Based on the biological rationale of IL-15 supplementation, correlative data from CD19 CAR-T cell studies, and results from preclinical studies with xenogeneic mouse models, NKTR-255 has the potential to augment currently approved cellular therapies.
- | NKTR-255 / Nektar Therap
Journal, CAR T-Cell Therapy, IO biomarker: A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR-T cell immunotherapy. (Pubmed Central) - Nov 5, 2022
P1/2
These data support an ongoing phase I clinical trial of combined CD19 CAR-T and NKTR-255 for R/R B-cell malignancies. This trial is registered at www.clinicaltrials.gov as NCT01865617.
- NKTR-255 / Nektar Therap
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_6482;
P1
NKTR-255 administration replenished dara-induced NK cell depletion. Optimal biological response of NKTR-255 monotherapy was observed between 6-9 µg/kg and will be further tested in Phase 2.
- NKTR-255 / Nektar Therap
A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (Hall D (Ernest N. Morial Convention Center)) - Nov 4, 2022 - Abstract #ASH2022ASH_4716;
P1
Based on preclinical and clinical evidence, NKTR-255 has the potential to improve efficacy of currently approved cellular therapies. This trial evaluates safety and efficacy of NKTR-255 following commercial CD19 CAR-T therapy to enhance antitumor effect and durability of responses.
- Bavencio (avelumab) / EMD Serono, Pfizer
JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma (Hall C) - Oct 5, 2022 - Abstract #SITC2022SITC_984;
P2, P3
After 4-10 weeks from end of chemotherapy, 252 patients will be randomized 1:2:2:2 to avelumab 800 mg every 2 weeks as monotherapy (control) or combined with sacituzumab govitecan (anti-Trop2/topoisomerase inhibitor conjugate) 10 mg/kg on days 1 and 8 of 21-day cycles, M6223 (anti-TIGIT) 1600 mg every 2 weeks, or NKTR-255 (IL-15 agonist) 3 μg/kg every 4 weeks...Secondary endpoints include OS, objective response and duration of response based on investigator assessment (RECIST 1.1), and pharmacokinetics. The trial opened in June 2022 with sites planned to recruit in the US, Europe, Asia, and Australia.
- || NKTR-255 / Nektar Therap
Enrollment status, Trial completion date, Trial primary completion date: NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 14, 2022
P1, N=118, Enrolling by invitation, Sponsor: Nektar Therapeutics
The trial opened in June 2022 with sites planned to recruit in the US, Europe, Asia, and Australia. Recruiting --> Enrolling by invitation | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
- || avipendekin pegol (NKTR-255) / Nektar Therap
Enrollment open, Combination therapy, CAR T-Cell Therapy: NCI-2022-02316: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - Aug 18, 2022
P1, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Center
Recruiting --> Enrolling by invitation | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Jun 2022 --> Mar 2023 Not yet recruiting --> Recruiting
- |||| Bavencio (avelumab) / EMD Serono
Enrollment open, Trial initiation date: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) (clinicaltrials.gov) - Aug 5, 2022
P2, N=252, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2022 --> Aug 2022
- | NKTR-255 / Nektar Therap
Journal, IO biomarker: Improving NK Cell Function in Multiple Myeloma with NKTR-255, a Novel Polymer-Conjugated Human IL-15. (Pubmed Central) - Jul 27, 2022
Finally, we observed that combination of NKTR-255 with the anti-CD38 antibody, daratumumab, was effective against MM cells in vitro and in vivo. Taken together, our data suggest a significant impact of NKTR-255 in inducing NK cell function against MM cells with important translational implications.
- || avipendekin pegol (NKTR-255) / Nektar Therap
Trial initiation date, Combination therapy, CAR T-Cell Therapy: NCI-2022-02316: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - May 28, 2022
P1, N=24, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Center
Taken together, our data suggest a significant impact of NKTR-255 in inducing NK cell function against MM cells with important translational implications. Initiation date: May 2022 --> Nov 2022
- || avipendekin pegol (NKTR-255) / Nektar Therap
New P1 trial, Combination therapy, CAR T-Cell Therapy: NCI-2022-02316: NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (clinicaltrials.gov) - May 2, 2022
P1, N=24, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Center
- NKTR-255 / Nektar Therap
Targeting Ewing sarcoma (ES), Osteosarcoma (OS) and Neuroblastoma (NB) with Anti MCAM Chimeric Antigen Receptor (CAR) Modified Natural Killer (NK) Cells () - Apr 20, 2022 - Abstract #ASPHO2022ASPHO_611;
NKTR-255 is an investigational IL-15Rα-dependent, polymer-conjugated, recombinant human IL- 15 agonist that retains the full spectrum of IL-15 biology, including expansion of NK cells (4,5)...Miyazaki, JITC, 2021 5. Robinson, JCI, 2021
- ||||| Bavencio (avelumab) / EMD Serono
New P2 trial: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) (clinicaltrials.gov) - Apr 13, 2022
P2, N=252, Not yet recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
- NKTR-255 / Nektar Therap
Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell-Mediated Cytotoxicity Combined with Anti-CD20 or Anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL) (Salt Palace Convention Center Hall A) - Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_934;
The in vivo effects of NKTR-255 with anti-CD19 CAR NK cells and Ritux, Ob or PV against rituximab-sensitive and -resistant BL cells using humanized NSG models are under investigation. (This work is funded by Children’s Cancer Fund Laboratory at New York Medical College and Rally foundation).